Q&A with Avacta's CEO Alastair Smith & CSO Fiona McLaughlin

Timestamps

• Progress on reformulating the RLFT. Start
• Update on the AVA6000 Phase 1 clinical trial. 03:00
• Significance of the Prodoxorubicin escalation. 05:05
• How is patient safety being measured? 06:45
• How many patients have been dosed thus far? 08:10
• Have the timescales been impacted by Covid related issues at hospitals? 08:25
• When is the pK data likely to be released? 09:45
• Anecdotally, what’s the broad level of confidence in how the pro-drug is performing (re efficacy). 11:00
• US Phase 1 clinical study for AVA6000. 11:45
• Selection of 2nd prodrug candidate (ie AVA3996). 12:30
• If the phase 1 data for AVA6000 is positive, what would this mean for the company? 14:20
•  Likewise, what would then be the commercialisation & funding options? 16:45
•  What are the key risks for the Phase 1 trial? 17:45
• Likely future news flow. 19:40